Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors: A study by the Italian Trials in Medical Oncology Group

Cancer

Volumn 77, Issue 2, 1996, Pages 402-408

  Di Bartolomeo, Maria ^a   Bajetta, Emilio ^a   Buzzoni, Roberto ^a   Mariani, Luigi ^a   Carnaghi, Carlo ^a   Somma, Luisa ^a   Zilembo, Nicoletta ^a   Di Leo, Angelo ^a   Gebbia, Vittorio ^b   Pinotti, Graziella ^c   Rabbi, Carla ^d   Franceschi, Tiziano ^e   Tumolo, Salvatore ^f   Visini, Marilena ^g   Artioli, Fabrizio ^h   Ballatore, Paolo ⁱ   Barni, Sandro ^j   Lorusso, Vito ^k   Mazzotta, Salvatore ^l   Bian, Alberto Rosa ^m  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Policlinico   (Italy)

^c OSPEDALE DI CIRCOLO   (Italy)

^d CARLO POMA HOSPITAL   (Italy)

^e UNIVERSITY HOSPITAL OF VERONA   (Italy)

^f CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^g A MANZONI HOSPITAL   (Italy)

^h Ospedale Ramazzini   (Italy)

ⁱ SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^j SAN GERARDO HOSPITAL   (Italy)

^k Istituto Oncologico   (Italy)

^l VITO FAZZI HOSPITAL   (Italy)

^m Ospedale Civile   (Italy)

more..

Author keywords

carcinoid; neuroendocrine tumor; octreotide; somatostatin analogue

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; OCTREOTIDE; SOMATOSTATIN DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CARCINOID SYNDROME; CHOLELITHIASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROENDOCRINE TUMOR; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STEATORRHEA; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR REGRESSION;

EID: 13344295073     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960115)77:2<402::AID-CNCR25>3.0.CO;2-4     Document Type: Article

References (31)

1. Williams ED, Siebenmann RE, Sobin LH. Histological typing of endocrine tumors. In: International Histological Classification of Tumors. Geneva: World Health Organization, 1980.
2. McKinnon JG. Palliative treatment of neuroendocrine tumors. Semin Surg Oncol 1993;9:453-8.
3. Zilembo N, Buzzoni R, Bajetta E, Di Bartolomeo M, de Braud F, Castellani R, et al. Salvage treatment after r-Interferon alpha 2a in advanced neuroendocrine tumors. Acta Oncol 1993;32:245-50.
4. Moertel CG, Johnson CM, Mc Kusick MA, Martin JK, Nagorney DM, Kvols LK, et al. The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann Intern Med 1994;120:302-9.
5. Ruszniewski P, Rougier P, Roche A, Lagmann P, Sibert A, Hochlaf S, et al. Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. Cancer 1993;71:2624-30.
6. Sharma D, Gurdip F, Grunberg SM. Chemotherapy of metastatic Merkel cell carcinoma: case report and review of literature. Am J Clin Oncol 1991;14:166-9.
7. Oberg K, Funa K, Aim G. Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with midgut carcinoid tumors and carcinoid syndrome. N Engl J Med 1983;309:129-33.
8. Moertel CG, Rubin J, Kvols LK. Therapy of metastatic carcinoid tumors and malignant carcinoid syndrome with recombinant leukocyte interferon. J Clin Oncol 1989;7:865-8.
9. Doberauer C, Mengelkoch B, Kloke O, Wandl U, Niederle N. Treatment of metastatic carcinoid tumors and carcinoid syndrome with recombinant interferon alpha. Acta Oncol 1991;30:603-5.
10. Oberg K, Norheim I, Lind E, Alm G, Lundqvist G, Wide L, et al. Treatment of malignant carcinoid tumors with human leukocyte interferon: long term results. Cancer Treat Rep 1986;70:1297-304.
11. Bajetta E, Zilembo N, Di Bartolomeo M, Di Leo A, Pilotti S, Bochicchio AM. Treatment of metastatic carcinoid and other neuroendocrine tumors with recombinant interferon alpha-2A. A study by the Italian Trials in Medical Oncology (I.T.M.O.) group. Cancer 1993;72:3099-105.
12. Di Bartolomeo M, Bajetta E, Zilembo N, de Braud F, Di Leo A, Verusio C, et al. Treatment of carcinoid syndrome with recombinant interferon alpha-2A. Acta Oncol 1993;32:235-8.
13. Reichlin S. Somatostatin. N Engl J Med 1983;309:1495-501.
14. Bauer W, Briner U, Doephner W. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982;31:1133-40.
15. Erikson LS, Wahren J. Intravenous and subcutaneous administration of long-activity somatostatin analogues: effects on glucose metabolism and splanchnic haemodynamics in healthy subjects. Eur J Clin Invest 1989;12:213-9.
16. Raynor K, Murphy WA, Coy DH, Taylor JE, Moreau JP, Yasuda K, et al. Cloned somatostatin receptor identification of subtype-selective peptides and demonstration of high affinity binding of linear peptides. Mol Pharmacol 1993;43:838-44.
17. Oberg K. Treatment of neuroendocrine tumors. Cancer Treat Rev 1994;20:331-55.
18. Antony LB, Winn S, Johnson DH, Jones RA, Hande KR, Oates JA. Continuous subcutaneous octreotide infusion for carcinoid tumor/syndrome [ASCO Proceedings Abstract n. 485]. J Clin Oncol 1992;11:168.
19. Kvols LK, Reubi JC. Treatment of metastatic carcinoid tumors with a somatostatin analogue (octreotide) and correlation of response with the presence of somatostatin receptors (Abstr N.35). In: International Symposium on Somatostatin, XX, Canada, August 1989.
20. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
21. Di Bartolomeo M, Bajetta E, Bochicchio AM, Carnaghi C, Somma L, Mazzaferro V, et al: A Phase II trial of dacarbazine, fluorouracil, and epirubicin in patients with neuroendocrine tumors. A study by the Italian Trials in Medical Oncology (I.T.M.O.) Group. Ann Oncol 1995;6:77-9.
22. Simon R. Optimal two-stage design of Phase II clinical trials. Control Clin Trials 1989;10:1-10.
23. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-81.
24. Bajetta E, Di Bartolomeo M, Zilembo N, Bochicchio AM. Medical treatment of neuroendocrine rumors. Tumori 1994;79:380-8.
25. Arnold R, Neuhaus C, Benning R, Schwerk WB, Trautmann ME, Joseph K, et al. Somatostatin analogue sandostatin and inhibition of tumor growth in patients with metastatic endocrine gastroenteropancreatic tumors. World J Surg 1993;17:511-9.
26. Saltz L, Trochanowski B, Buckley M, Hefferman B, Niedzwiecki D, Tao Y, et al. Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer 1993;72:244-8.
27. Dy DY, Morris DL. Somatostatin receptors in human gastrointestinal cancer. Int J Oncol 1993;3:519-23.
28. Evers MB, Hurlbut SC, Tyring SK, Townsend CH, Uchida T, Thompson JC. Novel therapy for the treatment of human carcinoids. Ann Surg 1991;213:411-6.
29. Öberg K. Chemotherapy and biotherapy in neuroendocrine tumors. Curr Opin Oncol 1993;5:110-20.
30. Antony LB, Krozely MG, Johnson DH, Fang CL, Hande RJ, Oates JA. Phase I trial of somatuline in neuroendocrine neoplasm [ASCO Proceedings Abstract n. 598]. J Clin Oncol 1993;12:202.
31. Pinski J, Schall AV, Halmos G, Szepeshazi K, Groot K, O'Byrne K, et al. Effects of somatostatin analogue RC-160 and Bombesin/Gastrin-releasing peptide antagonists on the growth of human small-ceil and non-small-cell lung carcinomas in nude mice. Br J Cancer 1994;70:886-72.